RxDoctor Payments Data

Steven Naids, MD

Ophthalmology · Boynton Beach, FLNPI 1487917530

Payments from drug & device makers

$52,269in general payments, 2019–2025

Across 373 payments — averaging $140.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$14K
  • Eyevance Pharmaceuticals LLC$14K
  • AbbVie$13K
  • Mallinckrodt Enterprises LLC$4K
  • Novartis$1K
  • Alcon$498
  • plus $6K from 29 others

What the payments were for

  • Consulting fees$10,40020%
  • Speaking & faculty fees$29,30056%
  • Travel & lodging$1,5773%
  • Food & beverage$10,85221%
  • Education$1400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,269 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$584,302
Medicare patients
1,228
Services billed
5,715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine595$461,600
XiidraLifitegrast127$110,760
LumiganBimatoprost219$90,868
XdemvyLotilaner16$30,148
CombiganBrimonidine Tartrate/Timolol78$29,280
Cyclosporine59$27,277
EysuvisLoteprednol Etabonate35$17,013
VyzultaLatanoprostene Bunod46$15,582
Prednisolone Acetate383$14,198
Latanoprost1,566$13,919
Lotemax SmLoteprednol Etabonate48$11,899
RocklatanNetarsudil Mesylat/Latanoprost13$10,874
Alphagan PBrimonidine Tartrate21$9,835
Restasis MultidoseCyclosporine16$9,827
IlevroNepafenac24$8,892

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P, Restasis Multidose$13,030$601,411929 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$357$126,342173 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$416$30,14816 claims
NovartisIlevro, Travatan Z$1,194$17,56041 claims
Kala Pharmaceuticals, Inc.Eysuvis$449$17,01335 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$246$15,84925 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate$14,270$13,62362 claims
AlconSimbrinza$498$6,45331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Boynton Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →